Cargando…
Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus
Antibodies capable of activating the complement system (CS) when bound with antigen are referred to as “complement-fixing antibodies” and are involved in protection against Flaviviruses. A complement-fixing antibody test has been used in the past to measure the ability of dengue virus (DENV)-specifi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584793/ https://www.ncbi.nlm.nih.gov/pubmed/34769432 http://dx.doi.org/10.3390/ijms222112004 |
_version_ | 1784597535217680384 |
---|---|
author | Nascimento, Eduardo J. M. Norwood, Brooke Parker, Allan Braun, Ralph Kpamegan, Eloi Dean, Hansi J. |
author_facet | Nascimento, Eduardo J. M. Norwood, Brooke Parker, Allan Braun, Ralph Kpamegan, Eloi Dean, Hansi J. |
author_sort | Nascimento, Eduardo J. M. |
collection | PubMed |
description | Antibodies capable of activating the complement system (CS) when bound with antigen are referred to as “complement-fixing antibodies” and are involved in protection against Flaviviruses. A complement-fixing antibody test has been used in the past to measure the ability of dengue virus (DENV)-specific serum antibodies to activate the CS. As originally developed, the test is time-consuming, cumbersome, and has limited sensitivity for DENV diagnosis. Here, we developed and characterized a novel multiplex anti-DENV complement-fixing assay based on the Luminex platform to quantitate serum antibodies against all four serotypes (DENV1-4) that activate the CS based on their ability to fix the complement component 1q (C1q). The assay demonstrated good reproducibility and showed equivalent performance to a DENV microneutralization assay that has been used to determine DENV serostatus. In non-human primates, antibodies produced in response to primary DENV1-4 infection induced C1q fixation on homologous and heterologous serotypes. Inter-serotype cross-reactivity was associated with homology of the envelope protein. Interestingly, the antibodies produced following vaccination against Zika virus fixed C1q on DENV. The anti-DENV complement fixing antibody assay represents an alternative approach to determine the quality of functional antibodies produced following DENV natural infection or vaccination and a biomarker for dengue serostatus, while providing insights about immunological cross-reactivity among different Flaviviruses. |
format | Online Article Text |
id | pubmed-8584793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85847932021-11-12 Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus Nascimento, Eduardo J. M. Norwood, Brooke Parker, Allan Braun, Ralph Kpamegan, Eloi Dean, Hansi J. Int J Mol Sci Article Antibodies capable of activating the complement system (CS) when bound with antigen are referred to as “complement-fixing antibodies” and are involved in protection against Flaviviruses. A complement-fixing antibody test has been used in the past to measure the ability of dengue virus (DENV)-specific serum antibodies to activate the CS. As originally developed, the test is time-consuming, cumbersome, and has limited sensitivity for DENV diagnosis. Here, we developed and characterized a novel multiplex anti-DENV complement-fixing assay based on the Luminex platform to quantitate serum antibodies against all four serotypes (DENV1-4) that activate the CS based on their ability to fix the complement component 1q (C1q). The assay demonstrated good reproducibility and showed equivalent performance to a DENV microneutralization assay that has been used to determine DENV serostatus. In non-human primates, antibodies produced in response to primary DENV1-4 infection induced C1q fixation on homologous and heterologous serotypes. Inter-serotype cross-reactivity was associated with homology of the envelope protein. Interestingly, the antibodies produced following vaccination against Zika virus fixed C1q on DENV. The anti-DENV complement fixing antibody assay represents an alternative approach to determine the quality of functional antibodies produced following DENV natural infection or vaccination and a biomarker for dengue serostatus, while providing insights about immunological cross-reactivity among different Flaviviruses. MDPI 2021-11-05 /pmc/articles/PMC8584793/ /pubmed/34769432 http://dx.doi.org/10.3390/ijms222112004 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nascimento, Eduardo J. M. Norwood, Brooke Parker, Allan Braun, Ralph Kpamegan, Eloi Dean, Hansi J. Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus |
title | Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus |
title_full | Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus |
title_fullStr | Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus |
title_full_unstemmed | Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus |
title_short | Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus |
title_sort | development and characterization of a multiplex assay to quantify complement-fixing antibodies against dengue virus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584793/ https://www.ncbi.nlm.nih.gov/pubmed/34769432 http://dx.doi.org/10.3390/ijms222112004 |
work_keys_str_mv | AT nascimentoeduardojm developmentandcharacterizationofamultiplexassaytoquantifycomplementfixingantibodiesagainstdenguevirus AT norwoodbrooke developmentandcharacterizationofamultiplexassaytoquantifycomplementfixingantibodiesagainstdenguevirus AT parkerallan developmentandcharacterizationofamultiplexassaytoquantifycomplementfixingantibodiesagainstdenguevirus AT braunralph developmentandcharacterizationofamultiplexassaytoquantifycomplementfixingantibodiesagainstdenguevirus AT kpameganeloi developmentandcharacterizationofamultiplexassaytoquantifycomplementfixingantibodiesagainstdenguevirus AT deanhansij developmentandcharacterizationofamultiplexassaytoquantifycomplementfixingantibodiesagainstdenguevirus |